Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Omeros : Shares Sink After Receiving JPMorgan's Neutral Rating

09/27/2021 | 01:47pm EDT


© MT Newswires 2021
All news about OMEROS CORPORATION
10/15SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omero..
PR
10/15OMEROS : UBS Adjusts Price Target on Omeros to $13 From $25 on Drug Filing Deficiencies, M..
MT
10/11OMEROS : Wedbush Suspended Coverage on Omeros
MT
10/08OMEROS : JPMorgan Downgrades Omeros to Underweight from Neutral
MT
10/07OMEROS ALERT : Bragar Eagel & Squire, P.C. is Investigating Omeros Corporation on Behalf o..
BU
10/07OMER EQUITY ALERT : ROSEN, LEADING INVESTOR COUNSEL, Encourages Omeros Corporation Investo..
PR
10/07INVESTIGATION NOTICE : The Schall Law Firm Announces it is Investigating Claims Against Om..
PR
10/06GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Announces Investigation..
BU
10/06OMEROS : HC Wainwright Adjusts Omeros' Price Target to $19 from $32, Keeps Buy Rating
MT
10/05INVESTOR ALERT : Law Offices of Howard G. Smith Announces Investigation of Omeros Corporat..
BU
More news
Analyst Recommendations on OMEROS CORPORATION
More recommendations
Financials (USD)
Sales 2021 108 M - -
Net income 2021 -126 M - -
Net Debt 2021 334 M - -
P/E ratio 2021 -3,97x
Yield 2021 -
Capitalization 483 M 483 M -
EV / Sales 2021 7,56x
EV / Sales 2022 5,14x
Nbr of Employees 277
Free-Float 95,9%
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 7,73 $
Average target price 22,50 $
Spread / Average Target 191%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Ray Aspiri Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION-45.89%483
CSL LIMITED5.08%100 638
WUXI BIOLOGICS (CAYMAN) INC.6.42%59 673
SAMSUNG BIOLOGICS CO.,LTD.5.21%48 619
BIOGEN INC.14.84%41 907
ALEXION PHARMACEUTICALS, INC.0.00%40 336